Boston Scientific to acquire Silk Road Medical for $1.26 billion, enhancing its vascular portfolio with Silk Road's TCAR system, a breakthrough in stroke prevention. Transaction closes in H2 2024.
Each week, Benzinga's Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks just under the surface and warrant attention.
Mizuho Securities raises target for Boston Scientific, predicting double-digit growth in cardiology. Surge in Farapulse adoption and Watchman FLX upside driving momentum.